Georgia Cancer Center at Augusta University | Strategic Alliance Partners

Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Drs Raval and Cortes discuss Dr. Cortes’ journey through the hematologic oncology field and highlight ongoing work in the hematologic oncology space.

Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.

Jorge Cortes, MD, inaugural editor-in-chief of Blood Global Hematology, details what type of research the new journal will highlight and its importance.

Building an innovative cancer research project takes time, creativity, and most importantly, a team of scientists working together on why a new way to treat cancer or keep the cancer from spreading to other parts of the body.

Marisol Miranda-Galvis, DDS, MS, PhD, discusses the investigation of disparities in survival outcomes of patients with hematologic malignancies relating to social determinants.

Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status.

The Georgia Cancer Center Pharmacogenomics Program has launched its pharmacogenomics testing services for Georgia Cancer Center patients and oncologists.

Acute myeloid leukemia is a cancer that affects blood cells in the bone marrow- the spongy tissue inside certain bones where new blood cells are made.

Anand P. Jillella, MD, has been selected as one of 20 Georgia “Trailblazers” in cancer care by the Georgia Center for Oncology Research and Education.

Multiple teams working inside the Georgia Cancer Center at the Medical College of Georgia at Augusta University are committed to closing care gaps across Georgia.

Cardiovascular diseases are the follow-up threats many men face after undergoing androgen deprivation therapy, also known as hormonal treatment, for prostate cancer.

Jorge E. Cortes, MD, has been an investigative leader for nearly 30 years in the development of numerous leukemia treatments.

The Paceline Ride, LLC team delivered a check for $126,000 to the Georgia Cancer Center at Augusta University.

The Augusta University community is encouraged to participate in this year’s Paceline bicycle ride on October 16.

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the challenges of using ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms (MPNs).

Jorge E. Cortes, MD, discusses managing treatment toxicities to optimize therapeutic outcomes in patients with CML and MPNs.

Jorge E. Cortes, MD, discusses the evolution of multiple myeloma treatment, the role of BCMA-directed therapies, and remaining questions that need to be addressed in this space

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the advantage of BCMA-targeted therapy in multiple myeloma.

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.

The future of treatment for ovarian cancer may lie in immunotherapy combinations with PARP inhibitors or checkpoint inhibitors.